Health Care • Biotechnology: Pharmaceutical Preparations
$7.64 ▼ -0.56
(-6.83%)
MKT CAP: $595.5M • VOL: 1.89M
52W L $6 52W H $13
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$6
MEDIAN
$9
MEAN
$9
HIGH
$10
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CRMD TAPE
CRMD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $9.24 | $8.79 | 2025-02-14 | $6.95 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $9.63 | $9.02 | 2025-02-06 | $7.18 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $8.71 | $8.40 | 2025-01-29 | $7.33 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $7.79 | — | 2025-01-17 | $7.49 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $6.72 | $7.26 | 2025-01-09 | $6.80 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $9.09 | $7.95 | 2024-12-18 | $6.65 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $7.41 | $7.72 | 2024-12-04 | $7.11 | -4.3% | 48% | C |